Next-IO™ CD47 × EGFR Dual-Targeted Therapeutic Fusion Protein Program

About This Program

This program aims to develop CD47 × EGFR dual-targeted therapeutic fusion protein for immuno-oncology.

Epidermal growth factor receptor (EGFR) plays an important role to regulate tumor cell growth, repair, and survival, angiogenesis, invasion, and metastasis. In many malignancies, EGFR expression associates with poor prognosis and low survival rate.

On the other hand, CD47 molecules are widely expressed on the cell surface of tumor cells. Researchers have successfully developed CD47 antagonists that could activate phagocytosis, enhance anti-tumor immune responses, and ultimately, achieve tumor growth inhibition.

Thus, we propose to develop an anti-CD47/EGFR bispecific antibody that could block EGFR-mediated activation of tumor cell proliferation and also, CD47-mediated tumor suppressor signaling, thereby activating immune responses. This combination may work better to inhibit tumor growth and proliferation than CD47/EGFR alone, highlighting a new outlook of cancer immunotherapy.

CD47 × EGFR in Cancer Studies

Here are some published data about CD47 × EGFR working as a potential target for cancer immunotherapy.

Therapeutic index evaluation of Bi-SP in A431 tumor xenografts.

CD47 × EGFR Dual-Targeted Therapeutic Fusion Protein Program (Yang, 2018)

Ongoing Clinical Trials

As far as we knew, NO bispecific anti-CD47 × EGFR antibody is undergoing a clinical trial. But accumulated preclinical data is emerging, further clarifying the synergistic anti-tumor effects of this bispecific combination. We believe CD47/MSLN is still a compelling bi-functional combination to research in cancer immunotherapy.
In an effort to optimally leverage CD47 × EGFR-mediated immune response, our next-generation CD47 × EGFR targeted antibody program attempts to explore the optimal combination strategy - that is, how to exert the best anti-tumor outcome while CD47 × EGFR is synergistically expressed.

Program Planning and Management

We have extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.

CD47 × EGFR Dual-Targeted Therapeutic Fusion Protein Program

Cooperation

Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop CD47 × EGFR Dual-Targeted Fusion Protein program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration.

Here are two ways for your choice, and please contact us for more details.

1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.

With our quality control protocol and knowledge of global regulatory requirements, we can help our partners further their research with more chance to succeed. Look forward to cooperating with you in the near future.

Reference

Yang, Y.; et al. A novel bispecific antibody fusion protein co-targeting EGFR and CD47 with enhanced therapeutic index. Biotechnology letters. 2018, 40(5): 789-795.

For Research Use Only | Not For Clinical Use